Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Medical therapy of paediatric inflammatory bowel disease

Antibodies targeting tumour necrosis factor have substantially advanced the treatment of paediatric inflammatory bowel disease. Understanding pharmacokinetics and therapeutic drug monitoring has led to increased efficacy and durability of response. Primary non-response is more common in ulcerative colitis than in Crohn’s disease, highlighting the need for alternative biologic agents and oral small molecules.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Turner, D. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570–1583 (2021).

    Article  CAS  Google Scholar 

  2. Kugathasan, S. et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet 389, 1710–1718 (2017).

    Article  Google Scholar 

  3. Dhaliwal, J. et al. Phenotypic variation in paediatric inflammatory bowel disease by age: a multicentre prospective inception cohort study of the Canadian Children IBD Network. J. Crohns Colitis 14, 445–454 (2020).

    Article  CAS  Google Scholar 

  4. Rinawi, F. et al. Long-term outcomes with adalimumab therapy in pediatric Crohn disease: associations with adalimumab exposure. J. Pediatr. Gastroenterol. Nutr. 74, 389–395 (2022).

    Article  CAS  Google Scholar 

  5. Assa, A. et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn’s disease compared with reactive monitoring. Gastroenterology 157, 985–996.e2 (2019).

    Article  CAS  Google Scholar 

  6. Mack, D. R. et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the medical management of pediatric luminal Crohn’s disease. Gastroenterology 157, 320–348 (2019).

    Article  Google Scholar 

  7. Dubinsky, M. C. et al. Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity. Inflamm. Bowel Dis. 28, 1375–1385 (2022).

    Article  Google Scholar 

  8. Ungaro, R. C. et al. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Aliment. Pharmacol. Ther. 51, 831–842 (2020).

    Article  Google Scholar 

  9. Hyams, J. S. et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet 393, 1708–1720 (2019).

    Article  Google Scholar 

  10. Church, P. C. et al. Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis. J. Crohns Colitis 13, 982–989 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Anne M. Griffiths.

Ethics declarations

Competing interests

A.M.G. has been a consultant for Abbvie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer and has received speaker fees from Abbvie and Janssen. L.S. declares no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scarallo, L., Griffiths, A.M. Medical therapy of paediatric inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 19, 685–686 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing